All Videos

In the third part of this five part series, Marc Wolman, labs manager, biopharmaceutical at PPD Laboratory services, GMP Lab, & Jurgen Hannig, senior principal scientist at PPD Laboratory services talk about new analytical tools for cell & gene therapies.

In the fourth part of this five-part series, Ryan Ellefson, director of lab informatics & data analytics, at PPD Laboratory services GMP Lab, and Benjamin Ziehr, senior group leader at PPD Laboratory services GMP Cell Lab, discuss data automation.

In the final segment of this five-part series, A CMC Roadmap to Cell and Gene Therapies, Derrick McVicker, group leader, at PPD Laboratory services, GMP Lab, discusses the transfer of bioanalytical methods to GMP Lab.

An interview with Tom Sellig the Chief Executive Officer of Adare Pharma Solutions at the CPHI Conference in Frankfurt, Germany.

This is the first segment of this three-part PPD Tech Talk series on Improving Clinical Trials with Innovative Data Solutions featuring experts Olivia Aspite and Bryan Neth of PPD®, part of Thermo Fisher Scientific.

This is the second segment of this three-part PPD Tech Talk series on Improving Clinical Trials with Innovative Data Solutions featuring experts Chris Clendening and Tim Rich.

This is the final segment of this three-part PPD Tech Talk series on Improving Clinical Trials with Innovative Data Solutions featuring experts John Maier and Renay Perry of PPD®, part of Thermo Fisher Scientific.

This video is an interview with Jon Brice, Vice President of Business Development at Asymchem at the AAPS Conference in Boston, Massachusetts.

Learn about the benefits of tailored active pharmaceutical ingredient [API] nanoparticles in this webinar with Christopher P. Worrall, Ph.D. This presentation looks at how API nanoparticles enable patient-centric therapies and benefit many dosage forms, as well as how industry collaborations drive novel drug delivery approaches.

Learn how TargTex partners with Nanoform to produce therapies for Glioblastoma patients. This process includes identifying novel targets with small molecules, utilizing Nanoform technology to increase the active pharmaceutical ingredient [API] concentration, and improving treatment stability to move the drug to clinical development.

Pharmaceutical Technology editors interview oral solid dosage development experts from Syntegon and Colorcon, with discussions centered on continuous OSD production, containment safety, and authentication at the dose level.

Pharmaceutical Technology editors interview aseptic and sterilization experts from Watson-Marlow Fluid Technology Solutions and Cherwell—diving into sterilization, aseptic processing, and the revised EU GMP Annex 1 guidance.

What does Ascendia do? What sets Ascendia apart from its competitors? What is Ascendia's company culture like?

Pharmaceutical Technology speaks with Jennifer Hurst, senior director at MasterControl.

In this exclusive Drug Digest video, experts from Roche and MilliporeSigma divulge factors that could influence an organization to pursue specific biomolecules for development.

CURIS® provides portable and fixed decontamination systems. CURIS® has revolutionized the biodecontamination world with efficacious hybrid hydrogen peroxide decontamination, which delivers a mix of vapor and micro-aerosols to each space at precisely calibrated intervals. Recent challenges in staffing for Life Sciences inspired CURIS® to help labs save time and money by creating a single system that completes multiple decontamination tasks in virtually any space, including as an integrated system for on-demand biodecontamination.

Sean Imlay, FG Clean Wipes, highlights the Saturix® Surface Cleaning System during INTERPHEX 2022. Watch this video to learn more about:

Ryan Downey, Director of Customer Operations, outlines August Bioservices’ capabilities for its customers and what it means to work with them.

Klaus Brinkrode, Sales Manager of Med. Tech Device Assembly & Labeling at Syntegon, explains their RMA machine and how it improves auto-injector assembly.

According to the International Energy Agency, COVID-19 initially lead to a “staggering” decline in energy demand and depressed energy prices. Less than two years later, we are now faced with the cost of energy at an all-time high. Rapidly growing demand and, more recently, the Russian invasion of Ukraine, are driving energy prices to unprecedented highs and challenging security of supply. It is against this backdrop of uncertainty that we are simultaneously attempting to avert climate disaster through how we generate, store, use and manage energy. Should renewable or net zero carbon targets be postponed or is this all part of the rocky road to net zero?

In this episode of Drug Digest, Pharmaceutical Technology editors, Felicity Thomas and Feliza Mirasol, examine the topic of emerging therapies in more detail, covering subjects such as the challenges of scale, the potential benefits of drug delivery innovation, importance of early analytical studies, the evolution of the regulatory landscape, and differences between regional regulatory requirements.

For decades, the power and potential of outsourcing has been viewed as a way for pharmaceutical companies to gain access to specialized domain expertise across geographic regions and achieve cost savings amidst a highly complex and diverse regulatory environment. In the face of dwindling drug pipelines, complex regulations and block-busters crossing their patent exclusivity, mature products offer a revenue stream for companies to sustain their bottom lines in a hyper-competitive global market.